



รายการอ้างอิง

1. Lipsky JJ. Mycophenolate mofetil. *Lancet* 1996; 348(9038):1357-9.
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. *Lancet* 1995; 345(8961):1321-5.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. *Transplantation* 1996; 61(7):1029-37.
4. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. *Transplantation* 1995; 60(3):225-32.
5. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. *Transplantation* 1997; 63(1):39-47.
6. Jirasiritham S, Sumethkul V, Mavichak V *et al*. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience. *Transplant Proc* 1998; 30(7):3576-7.
7. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology* 2000; 47(2-3):85-118.
8. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. *J Clin Pharmacol* 1996; 36(4):315-24.

9. Tsina I, Kaloostian M, Lee R, Tamowski T, Wong B. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. *J Chromatogr B Biomed Appl* 1996; 681(2):347-53.
10. Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. *J Clin Pharmacol* 1996; 36(4):332-44.
11. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. *Clin Pharmacokinet* 1998; 34(6):429-55.
12. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443--a phase I clinical trial and pilot rescue study. *Transplantation* 1992; 53(2):428-32.
13. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. *Transplantation* 1995; 60(3):225-32.
14. Wolfe EJ, Mathur V, Tomlanovich S *et al*. Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. *Pharmacotherapy* 1997; 17(3):591-8.
15. Takahashi K, Ochiai T, Uchida K *et al*. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan. *Transplant Proc* 1995; 27(1):1421-4.
16. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. *Transplant Proc* 1996; 28(2):925-9.
17. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. *Clin Chem* 1995; 41(7):1011-7.

18. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. *Br J Clin Pharmacol* 1996; 41(6):513-6.
19. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. *Transplant Proc* 1991; 23(2 Suppl 2):15-8.
20. Helderman JH, Goral S. Transplantation Immunology. In: Danovitch GM (eds), *Handbook of Kidney Transplantation* (2nd ed). New York: Little, Brown and Company, 1996: 14-31.
21. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. *Immunology today* 1996; Mar.
22. Delves PJ, Roitt IM. The Immune System. *N Eng J Med* 2000; 343(1): 37-49.
23. Atzpodien J, Dittmar KEJ. Immunologic Crosstalk. *N Eng J Med* 1999; 340(22): 1732.
24. Delves PJ, Roitt IM. The Immune System. *N Eng J Med* 2000; 343(2): 108-17.
25. Gudmundsdottir H, Turka LA. T cell Costimulatory Blockage: New Therapies for Transplant Rejection. *J Am Soc Nephrol* 1999; 10: 1356-65.
26. Holländer GA, Zuklys S. Förster E, et al. On Costimulatory Signals and T cell Tolerance: Relevance for Transplantation Immunity. *Transplant Proc* 1999; 31(Suppl 1/2A), 25S-32S.
27. Ward SG, June CH, Dlive D. PI 3 kinase : a pivotal pathway in T-cell activation?. *Immunology Today* 1996; 17(4): 187-97.
28. Arakelov A, Lakkis FG, The Alloimmune Response and Effector Mechanism of Allograft Rejection. *Semin Nephrol* 2000; 20(2): 95-102.
29. Young JE, Liu CC, Pedro M. Perforin-Dependent and Independent Pathways of Cytotoxicity Mediated by Lymphocytes. *Immuno Rev* 1998; 103: 161-202.
30. Raulet DH, Held W. Natural Killer Cell Receptors: The Offs and Ons of NK Cell Recognition. *Cell* 1995 Sep; 82: 697-700.

31. Genestier L, Bonnefoy-Berand N, Revillard JP. Apoptosis of Activated Peripheral T cells. *Transplant Proc* 1999; 31 (Suppl A) : 33S-38S.
32. Colvin RB, Cohen A, Sicaoz C, et al. Evaluation of the pathologic criteria for acute renal allograft rejection. Reproducibility, sensitivity and clinical correlation. *J Am Soc Nephrol* 1997; 8: 1939-41.
33. Halloran PF. The Immune Response to an Organ. Transplant. In: Wood K (eds), **The Handbook of Transplant Immunology.**
34. Lu CY, Penfield JG, Kielar ML, et al. Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process? *Kidney Int* 1999; 55: 2157-68.
35. Rossini AA, Greiner DL, Mordes JP. Induction of Immunologic Tolerance for Transplantation. *Am Physiol Soc* 1999; 79(1): 99-130.
36. Epstein FH. Antigen Localization and Migration in Immunity and Tolerance. *N Eng J Med* 1998; 339(26): 1905-13.
37. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. *Kidney Int* 1999; 56: 1967-79.
38. Brunet M, Martorell J, Oppenheimer F et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. *Transpl Int* 2000; 13 Suppl 1: S301-5.
39. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplatation. *Ther Drug Monit* 2000; 22(1): 14-9.



ประวัติผู้เขียนวิทยานิพนธ์

นาย วิเชียร จุฬาสรีกุล เกิดเมื่อวันที่ 16 ตุลาคม พ.ศ.2513 ที่จังหวัด ชลบุรี สำเร็จการศึกษาระดับมัธยมศึกษาตอนต้นจากรร.เตรียมอุดมศึกษาพัฒนาการ มัธยมศึกษาตอนปลายจากโรงเรียนเตรียมอุดมศึกษา จบแพทยศาสตรบัณฑิตจากคณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่ การศึกษา เมื่อปีพ.ศ. 2537 เข้าทำงานในตำแหน่งแพทย์ประจำแผนกอายุรกรรม โรงพยาบาลสมเด็จพระบรมราชเทวีฯ ณ ศรีราชา ระหว่างปีพ.ศ.2537-2539 จากนั้นได้รับทุนศึกษาต่อในสาขาอายุรศาสตร์ทั่วไปและอายุรศาสตร์สาขาวิชาโรคไต รวม 5 ปีที่ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ระหว่างปีพ.ศ.2539-ปัจจุบัน